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Chronic hepatitis B is one of the leading causes of hepatocellular
carcinoma (HCC) worldwide. Accurate prediction of HCC risk is
important for decisions on antiviral therapy and HCC surveil-
lance. In the last few years, a number of Asian groups have
derived and validated several HCC risk scores based on
well-known risk factors such as cirrhosis, age, male sex and high
viral load. Overall, these scores have high negative predictive val-
ues of over 95% in excluding HCC development in 3 to 10 years.
The REACH-B score was derived from a community cohort of
non-cirrhotic patients and is better applied in the primary care
setting. In contrast, the GAG-HCC and CU-HCC scores were
derived from hospital cohorts and include cirrhosis as a major
integral component. While the latter scores may be more applica-
ble to patients at specialist clinics, the diagnosis of cirrhosis
based on routine imaging and clinical parameters can be inaccu-
rate. To this end, recent developments in non-invasive tests of
liver ﬁbrosis may further reﬁne the risk prediction. The applica-
tion of HCC risk scores in patients on antiviral therapy and in
other ethnic groups should be evaluated in future studies.
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Chronic hepatitis B virus (HBV) infection affects over 350 million
people worldwide and remains one of the leading causes of cir-
rhosis, liver failure and hepatocellular carcinoma (HCC) [1]. In
the past three decades, we have witnessed major improvements
in the prevention and management of HBV-related HCC.
Universal immunization against HBV, now reaching 30 years in
some countries, effectively prevents new HBV infection and
HBV-related HCC [2]. A landmark randomized controlled trial
and multiple observational studies conﬁrmed that antiviral ther-
apy can profoundly reduce HCC risk in cirrhotic patients [3–5]. In
patients who have developed HCC, improvements in surgical,
locoregional and systemic therapies further contribute to better
survival [6]. In addition, antiviral therapy after liver resection
may reduce HCC recurrence and mortality [7–9].
At present, immunization has not covered people aged above
30 years, while the majority of HCC occur in middle-aged
patients. The full impact of universal immunization will take 2
to 3 more decades to manifest. Besides, antiviral therapy reduces
but cannot eliminate the risk of HCC. Therefore, HCC surveillance
is still indicated in at risk individuals.
HCC surveillance requires facilities and manpower resources
and may not be cost-effective in patients at low risk of HCC
[10]. With this background, several Asian groups have derived
and validated HCC risk scores based on well-known risk factors
to predict future HCC development in patients with chronic hep-
atitis B. Potential clinical applications of these risk scores include
prognostication and selection of patients for antiviral therapy and
HCC surveillance. The impact of antiviral therapy on HCC and an
introduction to the HCC risk scores have recently been reviewed
by the Journal [11]. This review further discusses the develop-
ment of HCC risk scores and the application in real-life clinical
practice, and highlights their roles and limitations in different
populations.15 vol. 63 j 722–732
JOURNAL OF HEPATOLOGY• Potent antiviral therapy reduces but does not eliminate 
the risk of hepatocellular carcinoma (HCC) in patients 
with chronic hepatitis B. Accurate HCC prediction is 
important to guide monitoring and surveillance for at-
risk patients.
• Risk factors of HCC can be divided into patient factors 
and viral factors. Cirrhosis is the single most important 
risk factor of HCC. Based on the risk factors, a number 
of risk scores have been developed and validated. 
The most studied scores include the GAG-HCC, CU-
HCC and REACH-B scores. Overall, the scores have 
excellent negative predictive values of over 95% in 
excluding HCC development in the next 3 to 10 years.
• Since antiviral therapy is an important disease modifier, 
the application of HCC risk scores in patients on 
antiviral therapy would overestimate the incidence of 
HCC. An updated score for treated patients is needed.
• The performance of the HCC risk scores appears to 
be inferior in Caucasian patients. It is unclear if it is 
because of geographical differences in the natural 
history of chronic hepatitis B or the effect of antiviral 
therapy.
• One potential pitfall of the HCC risk scores is the 
inclusion of cirrhosis as a major integral component 
while the diagnosis of cirrhosis is inaccurate. The recent 
development of non-invasive tests of fibrosis may 
potentially improve risk prediction further.
Key pointsRisk factors of HCC in HBV infection
Patient factors
Similar to other chronic liver diseases, cirrhosis is the single
most important risk factor for HCC in patients with chronic
hepatitis B (Table 1). In East Asian countries, the incidence of
HCC ranges from 0.2 per 100 person-years among inactive
carriers, 0.6 in patients with non-cirrhotic chronic hepatitis B
and 3.7 in those with compensated cirrhosis [12–14]. The
corresponding ﬁgures in Europe and the United States are
0.02, 0.3, and 2.2 per 100 person-years, respectively [12].
However, since HBV is directly carcinogenic, HCC may arise in
a non-cirrhotic liver. This highlights the importance of
considering other HCC risk factors in the management of
chronic hepatitis B.
As HCC usually develops in the background of liver injury and
cirrhosis which takes decades to develop, the incidence of HCC
increases with age. Moreover, studies have consistently shown
that men have higher rates of HCC than women, with male:
female ratios ranging from 2:1 to 4:1 [15]. This may be
because men are more likely to smoke, drink alcohol, and
have more active hepatitis and higher iron stores. Besides, both
estrogen and androgen receptors have been implicated inJournal of Hepatology 201hepatocarcinogenesis through the upregulation of interleukin-6
and cell cycle-related kinase [16,17].
It has long been observed that HCC runs in families. On aver-
age, ﬁrst-degree relatives of patients with HCC have a 2-fold
increase in HCC incidence [18,19]. The effect of family history
appears to be synergistic to HBV carriage [20]. Although the
observation can be partly explained by HBV infection and similar
lifestyles among family members, recent genomic studies have
begun to unravel genetic and epigenetic changes conducive to
HCC development [21–23].
On another note, chronic hepatitis B patients with obesity and
diabetes also have higher risk of HCC [24,25]. This is partly
explained by the increased ﬁbrosis progression in patients with
metabolic syndrome [26]. In fact, among cirrhotic patients who
used tenofovir for 5 years, regression of cirrhosis was less likely
in those with diabetes or high body mass index [27]. It remains
unclear whether the effect of metabolic syndrome on ﬁbrosis pro-
gression and hepatocarcinogenesis is mediated through concomi-
tant non-alcoholic steatohepatitis. In population studies, fatty
liver is less common in patients with chronic hepatitis B [28].
Viral factors
Patients with positive hepatitis B e antigen (HBeAg) and high
HBV DNA levels have increased risk of HCC. In a population study
of 11,893 men in Taiwan, the relative risk of HCC was 60.2 for
those with positive hepatitis B surface antigen (HBsAg) and
HBeAg and 9.6 for those with positive HBsAg alone, as compared
with those with negative HBsAg and HBeAg [29]. Furthermore,
baseline HBV DNA is associated with future HCC risk. In the
REVEAL-HBV Study, 3653 community non-cirrhotic patients with
positive HBsAg were followed up for a mean of 11.4 years [30].
The incidence of HCC was 108 per 100,000 person-years for
patients with HBV DNA below 300 copies/ml, 962 for those with
HBV DNA 100,000–999,999 copies/ml, and 1152 for those with
HBV DNAP1 million copies/ml. It should be noted that the study
included only Asian patients aged 30 to 65 years at baseline. The
ﬁndings cannot be extrapolated to younger patients, in whom
positive HBeAg and high HBV DNA are the hallmark of the
immune tolerance phase and are not associated with histological
activity and HCC development [31].
HBV is divided into different genotypes (A–H) based on aP8%
nucleotide sequence difference in the viral genome. Genotypes A
and D are originally prevalent in Europe, while genotypes B and C
are prevalent in Asia [32]. Due to the large inﬂux of immigrants in
North America and Europe, HBV genotypes vary widely within
these continents. Among different genotypes, genotype C is asso-
ciated with delayed HBeAg seroconversion [33]. Because of
longer immune clearance phase and prolonged liver injury,
patients with HBV genotype C infection are more likely to
develop cirrhosis [34] and have a 2- to 5-fold increase in the risk
of HCC [35–38]. Furthermore, the T1762/A1764 basal core pro-
moter mutant is more common in genotype C [39]. The muta-
tions are again associated with cirrhosis and HCC [37,39–41].
In recent years, there has been resurgence of interest in HBsAg
quantiﬁcation because the level probably reﬂects the level and
activity of intrahepatic covalently closed circular DNA [42]. A
study from Taiwan showed that on the whole HBV DNA is a bet-
ter predictor of HCC than HBsAg level [43]. However, among
patients with HBeAg-negative disease and low HBV DNA
<2000 IU/ml, an HBsAg level of P1000 IU/ml had a hazard ratio
of 13.7 for HCC as compared with lower HBsAg levels.5 vol. 63 j 722–732 723
Table 1. Risk factors of HCC in patients with chronic hepatitis B.
Patient factors Older age
Male gender
Family history of HCC
Genetic factors
Cirrhosis
Smoking
Alcohol consumption
Diabetes mellitus
Obesity
Exposure to aflatoxin
Viral factors High HBV DNA level
Positive hepatitis B e antigen
HBV genotypes
HBV mutations
Hepatitis B surface antigen level
Co-infection with hepatitis C virus, hepatitis D 
virus or HIV
HBV, hepatitis B virus; HCC, hepatocellular carcinoma.
Table 2. Recommendations on HCC surveillance by regional guidelines.⁄
AASLD [49] APASL [50] EASL-EORTC [51]
• Asian males over age 40
• Asian females over age
50
• Family history of HCC
• African/North American
blacks
• Cirrhosis 
• Cirrhosis • Cirrhosis
• Non-cirrhotic HBV
carriers with active
hepatitis
• Family history of
HCC
⁄The recommendations have been modiﬁed to focus on patients with chronic
hepatitis B.
AASLD, American Association for the Study of Liver Diseases; APASL, Asian Paciﬁc
Association for the Study of the Liver; EASL, European Association for the Study of
the Liver; EORTC, European Organisation for Research and Treatment of Cancer.
Training cohort with
longitudinal follow-up
Identification of independent factors 
associated with HCC
ReviewFinally, co-infection with hepatitis D virus and HIV clearly
increases the risk of disease progression, liver failure and HCC
[44–46]. On the other hand, data on the natural history of
HBV-hepatitis C virus co-infection are less consistent [47,48].Multivariable analysis to assign weighting to 
individual risk factors
Combine the risk factors
to form a risk score
Validation cohort with longitudinal follow-up to test 
the accuracy of the risk score
Fig. 1. Development of HCC risk scores.Current recommendations on HCC surveillance
Guidelines on HCC management have been issued by the
American Association for the Study of Liver Diseases (AASLD),
Asian Paciﬁc Association for the Study of the Liver (APASL) and
European Association for the Study of the Liver (EASL) (Table 2)
[49–51]. All three guidelines recommend HCC surveillance in
patients with compensated and decompensated cirrhosis.
Although the APASL guidelines acknowledge the occurrence of
HCC in the non-cirrhotic liver, it calls for further studies to deﬁne
the at risk group [50]. The EASL guidelines also recommend
surveillance in HBV carriers with active hepatitis and patients
with family history of HCC, but it is unclear what constitutes
active hepatitis [51]. In addition to cirrhosis and family history,
the AASLD guidelines speciﬁcally consider age, gender and ethnic
origin in selecting patients for surveillance [49]. In particular,
Africans and North American blacks have high risk of HCC and
are recommended for surveillance early regardless of their age
and disease status.
All three guidelines support 6-monthly HCC surveillance.
APASL recommends using abdominal ultrasonography and serum
alpha-fetoprotein (AFP) for surveillance [50]. In contrast, AASLD
and EASL recommend abdominal ultrasonography only because
of the limited sensitivity and speciﬁcity of serum HCC biomarkers
[49,51].HCC prediction in untreated patients
The recommendation by current guidelines is incomplete. If HCC
surveillance is restricted to cirrhotic patients, high risk
non-cirrhotic patients would be missed. On the other hand, indis-
criminate surveillance in low risk patients would impose heavy
burden on manpower and resources, particularly in developing
countries where HBV infection tends to be endemic. Although724 Journal of Hepatology 201the guidelines mention the consideration of disease severity
and risk factors, they remain undeﬁned. With this background,
several Asian groups derived and validated HCC risk scores to
predict HCC development in patients with chronic hepatitis B.
The methodology to develop HCC risk scores in the different
studies is similar (Fig. 1). First, risk factors associated with HCC
are identiﬁed in a cohort of patients with chronic hepatitis B
(training cohort or derivation cohort). The Cox proportional
hazard model is used if a survival analysis is performed.
Alternatively, binary logistic regression model may be used if
HCC is considered as a binary variable at a deﬁned time point
(e.g. 5 or 10 years). Based on the multivariable analysis,5 vol. 63 j 722–732
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independent HCC risk factors and their corresponding weights
are determined. This can be used to construct a risk score. The
most important ﬁnal step is to validate the accuracy of the risk
score in an independent cohort of patients (validation cohort).
This is because the risk score is modelled against the training
cohort and is bound to perform well in the same cohort.
GAG-HCC score
The GAG (Guide with age, gender, HBV DNA, core promoter
mutations and cirrhosis)-HCC score was derived from 820 hospi-
tal patients with chronic hepatitis B in Hong Kong (Table 3) [52].
During a mean follow-up of 77 months, 40 patients developed
HCC. In the original form, much importance was given to core
promoter mutations. Nevertheless, because core promoter muta-
tions would unlikely be tested in routine clinical practice, the
score was simpliﬁed to include the four remaining factors only.
Cirrhosis received the heaviest weighting, followed by male sex,
age and HBV DNA. Because of the relatively small sample size
and the small number of events, the cohort was not divided into
training and validation sets. Instead, the statistical method of
bootstrapping was performed. Overall, the area under the
receiver-operating characteristics curve (AUROC) for predicting
HCC in 5 and 10 years was 0.87 and 0.88, respectively. In the
cross-validation analysis, the negative predictive value at a
cut-off of 82 points to exclude HCC in 10 years approached
100%, while the positive predictive value was 26%.
CU-HCC score
The CU (Chinese University)-HCC score was derived in 1005 hos-
pital patients who participated in a prospective HCC surveillance
study led by oncologists [53] and validated in 424 patients at a
hospital clinic in Hong Kong [35]. The median follow-up of both
cohorts was 10 years [54]. HCC developed in 105 patients in
the training cohort and 45 patients in the validation cohort.
Hypoalbuminaemia and cirrhosis were the most important
factors, followed by HBV DNA, age and bilirubin. The AUROC for
predicting HCC in 5 and 10 years in the validation cohort was
0.76 and 0.78, respectively. At a cut-off of 5 points, the negative
predictive value to exclude HCC in 10 years was 97%, while the
positive predictive value was 27%.
Other than the low risk group, the study further deﬁned an
intermediate-risk group with a CU-HCC score of 5–19.5 and a
high risk group with a score of P20. In the validation cohort,
the 5- and 10-year HCC-free survival rates were 91% and 71% in
the intermediate-risk group, and 79% and 68% in the high risk
group, respectively.
REACH-B score
In 2010, the REVEAL-HBV investigators ﬁrst developed nomo-
grams for HCC prediction using data from 3653 patients [55].
The same investigators later reﬁned the analysis and developed
the REACH-B (risk estimation for hepatocellular carcinoma in
chronic hepatitis B) score, which was derived in 3584 community
patients in Taiwan and validated in 1505 hospital patients from
Hong Kong and Korea [56]. HCC developed in 131 patients in
the training cohort and 111 patients in the validation cohort.
Factors in the score include male sex, age, alanine aminotrans-
ferase (ALT), positive HBeAg and HBV DNA. The AUROC for pre-
dicting HCC in 5 and 10 years in the validation cohort was 0.80Journal of Hepatology 201and 0.77, respectively. Instead of using one or two cut-off values,
the REACH-B score offers granularity in risk prediction with a
score ranging from 0 to 17 points (Table 3). It is noteworthy that
the REACH-B score was derived in a community non-cirrhotic
cohort and therefore did not include cirrhosis as a predicting
factor. When the score was applied to cirrhotic patients in the
validation cohort, the AUROC was lower at 0.70 at 5 years and
0.65 at 10 years.
Additional molecular markers
The three scores above include mainly routine clinical parame-
ters because they are more likely to be used in real-life clinical
practice and were already available in the study cohorts.
Nonetheless, there are additional HCC risk factors not considered
in the scores above (see section on risk factors of HCC). These
potential markers may include HBsAg level, HBV genotype, HBV
mutations (e.g. core promoter mutation) and host mutations. In
a post-hoc analysis of the REVEAL-HBV cohort, the inclusion of
clinical and virological parameters of age, sex, ALT, family history
of HCC, HBeAg status, HBV DNA level, HBsAg level and HBV geno-
type allows the derivation of a composite score with an AUROC of
0.89, 0.85, and 0.86 in predicting HCC in 5, 10, and 15 years,
respectively (Table 3) [57]. On the other hand, HCC is genetically
a heterogeneous cancer. Few host gene polymorphisms confer
more than a 2-fold increase in HCC risk [58–60]. It is unlikely that
a single host mutation will have sufﬁcient impact on HCC predic-
tion. These markers may only be useful in clinical practice when
they have become more widely available and are better evaluated
in combination with traditional HCC risk factors.
Summary of natural history studies
The risk scores derived and validated in natural history cohorts
share similar predicting factors. Although the weighting and
selection of risk factors are slightly different, these scores have
similarly high negative predictive values to exclude HCC in
5–10 years. Notably, the studies did not exclude inactive HBV
carriers who would have low risk of HCC. Nonetheless, the scores
include components reﬂecting the features of inactive HBV carri-
ers and may be simpler for non-specialists and primary care
physicians to stratify the risk of their patients without the need
to understand in details the different stages of chronic hepatitis B.
The CU-HCC score identiﬁes not only the low risk group but
also the intermediate and high risk groups, while the REACH-B
score offers gradated risk prediction based on the individual
scores. It is however unclear if further categorization would
impact on clinical practice beyond prognostication. Arguably,
patients outside the low risk category should undergo regular
HCC surveillance anyway, and there is no evidence that patients
with even higher scores have faster growing tumors that warrant
more frequent surveillance. In fact, more frequent surveillance
has not been shown to increase uptake of curative treatment
and improve survival [61].HCC prediction in patients on nucleos(t)ide analogues
Asian data
The three HCC risk scores described above were derived and val-
idated in patient cohorts recruited in the 1990s and early 2000s,5 vol. 63 j 722–732 725
Table 3. HCC risk scores in untreated patients.
Risk score Patients Cirrhosis Calculation Interpretation
GAG-HCC 
score [52]
820 hospital 
patients in Hong 
Kong
No independent 
validation; 
bootstrap 
analysis used
15% Optimal cutoff: 82
Performance at 5 years:
Sensitivity: 70%
Specificity: 88%
Positive predictive value: 21%
Negative predictive value: 98%
Performance at 10 years:
Sensitivity: 100%
Specificity: 75%
Positive predictive value: 22%
Negative predictive value: 100%
CU-HCC 
score [54]
1005 hospital 
patients in Hong 
Kong in the 
training cohort; 
424 hospital 
patients in the 
validation cohort
38% 
in the 
derivation 
cohort; 
16% 
in the 
validation 
cohort
Optimal cutoff: 5
546 (54%) patients in the derivation cohort and 297 (70%) 
patients in the validation cohort were in the low risk group
Performance at 5 years:
Sensitivity: 78%
Specificity: 73%
Positive predictive value: 14%
Negative predictive value: 98%
Performance at 10 years:
Sensitivity: 81%
Specificity: 76%
Positive predictive value: 27%
Negative predictive value: 97%
REACH-B 
score [56]
3584 non-
cirrhotic 
community 
patients in 
Taiwan in the 
training cohort; 
1505 hospital 
patients in Hong 
Kong and Korea 
in the validation 
cohort
0% in the 
derivation 
cohort; 
18% 
in the 
validation 
cohort
5- and 10-year HCC risk by score:
<7: <1%, <1%
7: 0.5%, 1.2%
8: 0.8%, 2.0%
9: 1.2%, 3.2%
10: 2.0%, 5.2%
11: 3.3%, 8.4%
12: 5.3%, 13.4%
13: 8.5%, 21.0%
14: 13.6%, 32.0%
15: 21.3%, 46.8%
16: 32.4%, 64.4%
17: 47.4%, 81.6%
REVEAL 
risk model 
[57]
2227 non-
cirrhotic 
community 
patients in 
Taiwan in the 
training cohort; 
1113 patients 
non-cirrhotic 
patients from the 
same population 
as the validation 
cohort
0% AUROC:
5 years: 0.89
10 years: 0.85
15 years: 0.86
LSM-HCC 
score [79]
1035 hospital 
patients in Hong 
Kong in the 
training cohort; 
520 hospital 
patients from the 
same population 
as the validation 
cohort
32% 
in the 
derivation 
cohort; 
31% 
in the 
validation 
cohort
14 * sex (male = 1; female = 0) 
+ age (in years) + 3 * HBV DNA 
(log copies/ml) + 33 * cirrhosis
(presence = 1; absence = 0)
Age (>50 years = 3; ≤50 = 0) + 
albumin (≤35 g/L = 20; >35 = 0) + 
bilirubin (>18 μmol/L = 1.5; <18 = 
0) + HBV DNA (<4 log copies/ml 
= 0; 4-6 = 1; >6 = 4) + cirrhosis 
(yes = 15; no = 0)
Male sex: 2 points
Age: 1 point for every 5 years 
from 35 to 65 years of age (0-6 
points)
ALT (IU/L): 15-44 (1 point), ≥45 (2 
points)
Positive HBeAg: 2 points
HBV DNA (log copies/ml): 4-5 
(3 points), 5-6 (5 points), ≥6 (4 
points)
Age (1 point for each 5 years) + 
sex (male = 2; female = 0) + ALT 
(IU/L; <15 = 0; 15-44 = 1; ≥45 = 
2) + family history of HCC (No = 
0; Yes = 2) + composite 
virological factors
Virological factors:
HBeAg/HBV DNA/HBsAg/
Genotype
Negative/<104/<100/any: 0 
Negative/<104/≥100/any: 2 
Negative/104-106/<1000/any: 3 
Negative/104-106/≥1000/any: 4 
Negative/≥106/any/B or B+C: 5 
Negative/≥106/any/C: 7 
Positive/any/any/B or B+C: 6 
Positive/any/any/C: 7
Age (>50 years = 10; <50 = 0) + 
albumin (≤35 g/L = 1; >35 = 0) + 
HBV DNA (>200,000 IU/ml = 5; 
≤200,000 = 0) + liver stiffness 
(≤8.0 kPa = 0; 8.1-12.0 = 8;
>12.0 = 14)
Optimal cutoff: 11
706 (68%) patients in the derivation cohort and 362 (70%) 
patients in the validation cohort were in the low risk group
Performance at 5 years:
Sensitivity: 92%
Specificity: 71%
Positive predictive value: 8%
Negative predictive value: 100%
ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.
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Table 4. HCC risk scores in patients on oral nucleos(t)ide analogues.
Study Wong 2013 [63] Arends 2014 [68] Papatheodoridis 2014/2015 [69, 70]
N 1531 (entire Chinese 
cohort; 332 had 
cirrhosis)
744 (entire multi-
ethnicity cohort; 164 
had cirrhosis)
316 (Caucasian 
subgroup)
1666 (entire Caucasian 
cohort)
531 (cirrhotic subgroup)
GAG-HCC 
score
Baseline c-statistics 
0.76, sensitivity at the 
last follow-up 55%, 
NPV 98%
After 2 years of 
antiviral therapy 
c-statistics 0.86, 
sensitivity 68%, NPV 
99%
Baseline c-statistics 
0.85, sensitivity at 4 
years 18%, NPV 95%
After 1 year of antiviral 
therapy c-statistics 
0.84, sensitivity at 4 
years 11%, NPV 95%
Baseline c-statistics 
0.74, sensitivity at 
4 years 25%, NPV 
97%
After 1 year of 
antiviral therapy 
c-statistics 0.77, 
sensitivity at 4 years 
25%, NPV 97%
Baseline c-statistics 
0.76
Hazard ratio
Score <101: ref
Score ≥101: 5.8
Baseline c-statistics 0.62
Hazard ratio
Score <101: ref
Score ≥101: 2.4
CU-HCC 
score
Baseline c-statistics 
0.80, sensitivity at the 
last follow-up 94%, 
NPV 100%
After 2 years of 
antiviral therapy 
c-statistics 0.85, 
sensitivity 86%, NPV 
100%
Baseline c-statistics 
0.78, sensitivity at 4 
years 78%, NPV 98%
After 1 year of antiviral 
therapy c-statistics 
0.73, sensitivity at 4 
years 89%, NPV 98%
Baseline c-statistics 
0.66, sensitivity at 
4 years 67%, NPV 
98%
After 1 year of 
antiviral therapy 
c-statistics 0.71, 
sensitivity at 4 years 
75%, NPV 97%
Baseline c-statistics 
0.62
Hazard ratio
Score <5: ref
Score 5-20: 2.3
Score >20: 5.7
Baseline c-statistics 0.64
Hazard ratio
Score <5: -
Score 5-20: ref
Score >20: 1.3
REACH-B 
score
Baseline c-statistics 
0.71, sensitivity at the 
last follow-up 95%, 
NPV 100%
After 2 years of 
antiviral therapy 
c-statistics 0.79, 
sensitivity 100%, 
NPV 100%
Baseline c-statistics 
0.71, sensitivity at 4 
years 82%, NPV 95%
After 1 year of antiviral 
therapy c-statistics 
0.79, sensitivity at 4 
years 50%, NPV 97%
Baseline c-statistics 
0.54, sensitivity at 
4 years 75%, NPV 
96%
After 1 year of 
antiviral therapy 
c-statistics 0.65, 
sensitivity at 4 years 
0%, NPV 97%
Baseline c-statistics 
0.61
Hazard ratio
Score <8: ref
Score ≥8: 3.2
Baseline c-statistics 0.61
Hazard ratio
Score <8: ref
Score ≥8: 1.9
PAGE-B 
score*
- - - Baseline c-statistics 
0.82, sensitivity at the 
first 5 years 100%, 
specificity 20%, PPV 
9%, NPV 100%
-
⁄The PAGE-B score is calculated as age (<30 years = 4; 30–39 = 2; 40–49 = 0; 50–59 = 2; 60–69 = 4;P70 = 6) + sex (male = 5; female = 0) + platelet count ( 1000/mm3;
P200 = 0; 100–199 = 6; <100 = 11). The optimal cut-off in the original study was 6 points or above. Please refer to Table 3 regarding the proposed cut-offs of the other
scores.
AUROC, area under the receiver-operating characteristics curve; NPV, negative predictive value; PPV, positive predictive value.
JOURNAL OF HEPATOLOGYwhen antiviral therapy was not widely available. Nowadays,
antiviral therapy is the standard treatment in patients at risk of
HCC. Predictors of HCC may no longer apply in treated patients.
Moreover, antiviral therapy modiﬁes the natural history of
chronic hepatitis B [3–5]. Risk factors of HCC such as HBeAg sta-
tus, HBV DNA, ALT and cirrhosis may alter after treatment [62]. It
is unclear how one should interpret changes in risk scores after
antiviral therapy.
The performance of HCC risk scores in treated patients has
been tested in a cohort of 1531 patients from Hong Kong
(Table 4) [63]. The patients were treated with entecavir 0.5 mg
daily for a mean of 42 months. Apart from using a treatment
cohort, this study evaluated not only baseline predictors but also
serial on-treatment data. Overall, the time-dependent AUROC for
predicting HCC development was 0.76–0.95 for the GAG-HCC
score, 0.77–0.95 for the CU-HCC score, and 0.71–0.97 for the
REACH-B score. The negative predictive values, according to the
published cut-offs, of both the baseline and on-treatment scores
to exclude HCC were 98–100% for all three scores. On the other
hand, the positive predictive values of the scores were only
0.2–10.3%. In other words, because antiviral therapy furtherJournal of Hepatology 201reduces the risk of HCC, treated patients with low risk scores
have very low risk of HCC. Although HCC surveillance is still
required in patients with high risk scores, the risk is also consid-
erably lower than that of untreated patients.
The second aim of the study was to determine the clinical
meaning of an improvement in risk scores during antiviral ther-
apy. For both the GAG-HCC and CU-HCC scores, patients who
had high risk scores at baseline and low risk scores 2 years after
entecavir treatment had their HCC incidence reduced by more
than half compared with those whose risk scores remained high.
Nonetheless, their HCC incidence remained higher than that of
patients with low risk scores at baseline. In the latter group,
the incidence of HCC was <1% in 5 years.
Although the study suggests that the HCC risk scores can also
be applied to treated patients to exclude future HCC develop-
ment, it should be noted that not all components of the risk
scores were important HCC risk factors. In particular, a baseline
or on-treatment HBV DNA level of P2000 IU/ml was no longer
associated with HCC. Instead, complete HBV DNA suppression
and the duration of complete HBV DNA suppression were associ-
ated with HCC-free survival in cirrhotic patients [63]. The5 vol. 63 j 722–732 727
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increased risk of disease progression and HCC development in
treated patients with incomplete viral suppression has been inde-
pendently conﬁrmed in European and Korean cohorts [64,65].
This observation has two clinical implications. First, combination
therapy or new treatment modalities may be needed in patients
with incomplete HBV DNA suppression [66]. Second, HCC risk
scores may need to be reﬁned for patients on antiviral therapy.
In particular, since the majority of patients on entecavir and teno-
fovir treatment would have undetectable or very low level of HBV
DNA, it may be necessary to use a lower HBV DNA cut-off in the
risk scores. Alternatively, if HBV DNA is already insufﬁciently dis-
criminatory in treated patients, it may have to be supplemented
by other biomarkers such as HBsAg levels. Quantitative HBsAg
has been tested as a biomarker of peginterferon response in
chronic hepatitis B patients and can be used to predict sponta-
neous and treatment-induced HBsAg seroclearance [42]. HBsAg
levels correlate with HCC in patients with low-to-moderate but
not high HBV DNA [67]. Hence, this marker may be most relevant
in patients on antiviral therapy.
Do HCC risk scores work in other populations?
Since the above risk scores were all developed in Asian popula-
tions, the obvious question is whether they can be applied to
other ethnic groups. There are reasons to suspect they may not.
First, perinatal transmission accounts for over 90% of HBV infec-
tion in Asia. As a result, Asian patients typically have a long per-
iod of immune tolerance phase (20–40 years) before entering into
the immune clearance phase [1]. In contrast, horizontal transmis-
sion through unsafe sex practice and parenteral exposure is more
common in Western countries. Patients acquiring HBV infection
during adulthood do not go through the immune tolerance phase,
and the interpretation and prognostic signiﬁcance of the virolog-
ical markers can be starkly different. Besides, because patients
acquiring HBV through perinatal and horizontal transmission
have different duration of infection, the incidence of cirrhosis
and HCC is also different for patients at the same age. Finally,
genetic differences of different ethnic groups may also contribute
to a difference in the natural history of disease. Based on a sys-
tematic review of observational studies, the 5-year cumulative
risk of HCC in cirrhotic patients is 17% in East Asia and 10% in
Western Europe [12].
To date, HCC risk scores have been tested in two Western
cohorts. In the Vigilance against Viral Resistance (VIRGIL)
Surveillance Study, 744 patients with HBV monoinfection were
treated with entecavir at 11 European centres [68]. 42% were
Caucasians and 29% were Asians. During a median follow-up of
167 weeks, 14 patients developed HCC, of whom nine had cirrho-
sis at baseline and seven were Caucasians. The AUROC for HCC
prediction of the GAG-HCC, CU-HCC and REACH-B scores in the
entire cohort was 0.85, 0.78, and 0.71, respectively. The corre-
sponding AUROC in Caucasian patients was 0.74, 0.66, and 0.54,
respectively. The negative predictive values at the proposed
cut-offs to exclude HCC at 4 years were 95%, 98%, and 95%,
respectively (Table 4).
Although the VIRGIL results suggest the risk scores may not
perform as well in Caucasians, the short duration of follow-up
and the small number of Caucasian patients with HCC preclude
ﬁrm conclusions. Therefore, another multi-centre retrospective
study was conducted to address this issue. 1666 patients from
seven centres in Europe and Canada were treated with entecavir728 Journal of Hepatology 201or tenofovir disoproxil fumarate [69]. The diagnosis of cirrhosis
was based on histology, ultrasonographic ﬁndings or clinical
portal hypertension. 28.6% of the patients had compensated
cirrhosis and 3.3% had decompensated cirrhosis. During a median
follow-up of 39 months, 71 developed HCC. In the entire popula-
tion, the AUROC for HCC prediction of the GAG-HCC, CU-HCC, and
REACH-B scores was 0.76, 0.62, and 0.61, respectively. In the
PAGE-B score derived from this cohort, older age, male gender
and low platelet count were the independent factors associated
with HCC development (Table 4) [70]. It is however difﬁcult to
distinguish whether the difference in score performance is due
to ethnic inﬂuence or the disease-modifying effect of antiviral
therapy. Suggestions on future research direction are listed in
Table 5.Diagnosis of cirrhosis as the Achilles heel
Cirrhosis is the single most important risk factor of HCC and is an
integral component of the GAG-HCC and CU-HCC scores. Current
HBV treatment guidelines recommend liver biopsy in patients
with borderline treatment indications [71–73], but the procedure
is limited by its invasiveness and poor patient acceptance. In
routine clinical practice, the diagnosis of cirrhosis is not
uncommonly based on abdominal ultrasonography or clinical
features of portal hypertension such as varices, ascites and
splenomegaly. Early cirrhosis is often undiagnosed and the risk
of HCC would be underestimated. The CU-HCC score partially
compensates by including surrogates of cirrhosis such as albumin
and bilirubin levels, but those are again insensitive markers of
early cirrhosis [54].
In recent years, liver stiffness measurement (LSM) by tran-
sient elastography (FibroScan, Echosens, Paris, France) has
become a popular non-invasive test of liver ﬁbrosis in Europe
and Asia [74]. It is highly reproducible and has been validated
against liver histology in patients with chronic hepatitis B
[75–77]. The accuracy of LSM in diagnosing cirrhosis is good, with
an AUROC of 0.80–0.95.
Because LSM can accurately diagnose cirrhosis, it comes as no
surprise that chronic hepatitis B patients with high LSM have
increased risk of HCC. In a Korean cohort of 1130 patients with
chronic hepatitis B followed for a median of 31 months, baseline
LSM correlated with HCC risk in a dose-dependent manner [78].
Compared with patients with LSM 68.0 kPa, the hazard ratios
of HCC for patients with LSM 8.1–13.0 kPa, 13.1–18.0 kPa, 13.1–
23.0 kPa, and >23.0 kPa were 3.1, 4.7, 5.6, and 6.6, respectively.
Since liver ﬁbrosis and cirrhosis is just one of the risk factors
of HCC in patients with chronic hepatitis B, it would be incom-
plete to rely on LSM alone to guide HCC surveillance. In a
prospective cohort of 1555 patients in Hong Kong, LSM was com-
bined with other clinical parameters to optimize the CU-HCC
score [79]. During a mean follow-up of 69 months, 55 patients
developed HCC. Independent predictors of HCC included age
>50 years, albumin 635 g/L, high HBV DNA and increased LSM
(Table 3). After adjusting for other predictors, the hazard ratios
for HCC were 3.9 for an LSM of 8.1–12.0 kPa and 6.0 for an LSM
of >12.0 kPa. The AUROC of the LSM-HCC score was 0.89 at
3 years and 0.83 at 5 years; the corresponding AUROC of the
CU-HCC score was 0.81 and 0.75, respectively. In another
Korean cohort of 1250 patients with chronic hepatitis B followed
for a median of 31 months, 56 patients developed HCC and the5 vol. 63 j 722–732
Table 5. Future research directions in HCC prediction.
Optimize HCC risk scores for patients on antiviral therapy
Reevaluate predictors of HCC in Caucasian cohorts with longer duration of follow-up
Further incorporate elastography and serum tests of fibrosis in HCC risk scores
Explore the role of combined HCC risk prediction and surveillance using image-based techniques with a component of fibrosis 
assessment (e.g. acoustic radiation force impulse, shear-wave elastography, magnetic resonance elastography)
Explore the role of other HCC risk factors (e.g. HBV genotypes, core promoter mutations, host genetics) as components of the risk 
scores
Defining surveillance interval in patients with different risk levels using overall mortality as endpoint
Explore the use of additional tumor markers and imaging for HCC surveillance in high-risk patients
JOURNAL OF HEPATOLOGYrisk factors of HCC included age, male gender, LSM and HBV DNA
[80]. A regression formula including the four factors achieved an
AUROC of 0.81 in predicting HCC. Similarly, in a smaller cohort of
192 patients with complete virological response with entecavir
treatment from the same group, 25 patients developed
liver-related events, including 15 having HCCs [57]. The addition
of LSM to the REACH-B score had a higher AUROC to predict
liver-related events than REACH-B score alone (0.81 vs. 0.63).
Though the initial results are promising, it should be noted
that transient elastography measures liver stiffness as a surrogate
for ﬁbrosis. Liver stiffness may also increase during active hepatic
necroinﬂammation [81,82], heart failure [83], biliary obstruction
[84] and food intake [85]. In particular, high ALT level contributes
to increased liver stiffness. After ALT normalization with antiviral
therapy, the liver stiffness typically declines even without regres-
sion of ﬁbrosis [86]. Whether the on-treatment liver stiffness
remains robust in prognostication is currently unclear.
Other than transient elastography, acoustic radiation force
impulse, shear-wave elsatography and magnetic resonance elas-
tography also provides physical measurements of liver elasticity
or stiffness and have been used to diagnose cirrhosis in chronic
hepatitis B [87–89]. However, these techniques have not been
extensively evaluated. The optimal cut-offs and their roles in
HCC prediction are yet to be deﬁned.
In addition, a number of serum tests have been developed to
aid the diagnosis of cirrhosis. Some serum tests make use of rou-
tine clinical parameters such as aspartate aminotransferase
(AST)-to-ALT ratio, AST-to-platelet ratio index and the Hui’s index
(body mass index, platelet count, albumin and bilirubin) [90,91].
Other tests adopt speciﬁc biomarkers of ﬁbrosis and have been
commercialized as combined panels (e.g. FibroTest, enhanced
liver ﬁbrosis panel) [92,93]. Abnormal ﬁbrosis biomarkers are
associated with HCC development [94]. Further studies are
required to evaluate the possibility of combining these serum
tests with other clinical parameters to improve HCC prediction.Howmay the knowledge of HCC risk be translated into clinical
practice?
Since all studies consistently showed that patients in the low risk
group comprise over half of the population and have minimal risk
of HCC in the next 3–5 years, it is reasonable and probably
cost-effective to repeat abdominal ultrasonography in 3 years
unless the clinical condition changes in between. We still recom-
mend 6-monthly surveillance by abdominal ultrasonography for
all patients outside the low risk group. Although some risk scoresJournal of Hepatology 201allow further differentiation of patients into different levels of
risk, there is yet evidence to show a survival beneﬁt in high risk
patients receiving more frequent surveillance.
If more frequent ultrasonography does not help, is it possible
to use better tumor markers and imaging for surveillance in high
risk patients? Other than AFP, the Lens culinaris agglutinin-
reactive glycoform of AFP (AFP-L3), des-c-carboxyprothrombin,
Golgi protein 73 and osteopontin have been evaluated in the
screening population [95,96]. On the whole, these tumor markers
have modest performance but may pick up a proportion of
AFP-negative HCCs. Furthermore, the use of computed tomogra-
phy and magnetic resonance imaging improves the detection of
HCC particularly in cirrhotic patients [97]. While it is unrealistic
to use expensive cross-sectional imaging for surveillance in every
patient with chronic hepatitis B, their use in high risk patients
should be further evaluated.Conclusions
Despite variable performance of the HCC risk scores in different
populations, they consistently demonstrate high negative predic-
tive values to exclude HCC development in the next 3 to 10 years
in Asian and Caucasian chronic hepatitis B patients with and
without antiviral therapy. While the performance of the risk
scores appears to differ in cirrhotic and non-cirrhotic patients,
it may be impractical to apply different scores for different
populations in real-life practice, especially as the diagnosis of
cirrhosis may be inaccurate. Instead, the inclusion of
non-invasive tests of ﬁbrosis in risk prediction should be more
clinically meaningful. The apparent inferior performance of HCC
risk scores in Caucasians may be explained by ethnic difference
in the natural history of chronic hepatitis B, different proportion
of patients with cirrhosis, short duration of follow-up and the
inﬂuence of antiviral therapy. In any case, antiviral therapy is
clearly an important disease modiﬁer in both Asian and
Caucasian patients. An updated HCC risk score for treated
patients is likely needed.Conﬂict of interest
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